Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

olverembatinib

olverembatinib is a bcr/abl fusion protein inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 9
News articles 1
Drug details — olverembatinib
Class
—
Route
—
Patents
0
Programs
9
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

olverembatinib is a bcr/abl fusion protein inhibitor.

Key facts

INN olverembatinib
Mechanism Bcr/Abl fusion protein inhibitor
Target Bcr/Abl fusion protein

Mechanism of action

Bcr/Abl fusion protein inhibitor

Primary target: Bcr/Abl fusion protein

Approval history

Authority Status Date
NMPA clinical trials —

Recent coverage

View all news
Ascentage Pharma's Olverembatinib Update: Insights from ASCO 2026
Medium impact AnalysisCML-CPJun 1, 2026

Ascentage Pharma's Olverembatinib Update: Insights from ASCO 2026

EMA · CML-CP · 2 min

Ascentage Pharma has unveiled updated clinical data for Olverembatinib at ASCO 2026, highlighting its potential as a second-line therapy in CML-CP. This article delves into the implications for investors and pharma teams.

Dr. Elena Rossi

Pipeline programs

Browse pipeline
  1. HQP1351AG301 Phase 3 · Anaxis Pharma · Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymph
  2. HQP1351CG301 Phase 3 · Anaxis Pharma · Chronic Phase Chronic Myeloid Leukemia
  3. Olverembatinib Phase 3 · Ascentage Pharma · Ph+ ALL
  4. Olverembatinib Phase 2 · First People's Hospital · Myeloproliferative Neoplasm
  5. Olverembatinib Phase 2 · Chinese Academy of · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemi
  6. Olverembatinib Phase 2 · First People's Hospital · Philadelphia-Positive ALL
  7. Olverembatinib+INO Phase 2 · Chinese Academy of · HSCT
  8. HQP1351ACE01 Phase 1 · Chinese Academy of · Lymphoblastic Leukemia, Acute, Childhood

Related & competitor drugs

Browse all drugs
  1. dasatinib Antineoplastic and immunomodulating agents (L01)
  2. imatinib mesylate Platelet-derived growth factor receptor beta inhibitor
  3. ponatinib hydrochloride Bcr/Abl fusion protein inhibitor
  4. asciminib hydrochloride Bcr/Abl fusion protein inhibitor
  5. bosutinib monohydrate Bcr/Abl fusion protein
  6. nilotinib hydrochloride Bcr/Abl fusion protein inhibitor

Frequently asked questions

What is olverembatinib?

olverembatinib is a bcr/abl fusion protein inhibitor.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.